Efficacy and safety of direct oral anticoagulants in patients with implanted inferior vena cava filters: a systematic review and meta-analysis
Open Access
- 16 November 2024
- journal article
- review article
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (2) , 32-43
Abstract
Nowadays, vitamin K antagonists (VKA) remain the anticoagulants of choice for patients with implanted inferior vena cava (IVC) filters, while the use of direct oral anticoagulants (DOACs) is controversial. Aim of the review – the study aimed to compare the efficacy and safety of DOACs and VKAs in patients with IVC filters. A systematic search for the relevant papers was performed in Medline (Pubmed) and the Cochrane Library according to the PRISMA guidelines. The inclusion criteria for the analysis were as follows: comparative studies of any design that enrolled patients with verified venous thromboembolism (VTE) who underwent IVC filter implantation and received long-term therapy with DOACs or VKAs with reported numbers of thrombotic and hemorrhagic complications within a follow-up of ≥3 months. The primary endpoints were VTE recurrence and major bleeding. Secondary endpoints included deep vein thrombosis (DVT), IVC thrombosis or filter occlusion, pulmonary embolism (PE), clinically relevant non-major (CRNM) bleeding, any bleeding, and all-cause mortality. Meta-analysis was performed using a random or fixed-effect model depending on the identified heterogeneity. As a result of the literature search was performed in July 2024 and identified 189 references, of which four articles were selected for full-text analysis after screening and excluding 174 irrelevant papers. The final qualitative analysis and quantitative synthesis included two retrospective cohort studies of 302 patients comparing rivaroxaban and warfarin. There were no significant differences between rivaroxaban and warfarin according to the prespecified endpoints. Rivaroxaban is the only DOAC studied in patients with IVC filters. Anticoagulation with rivaroxaban is not less effective and safe than with warfarin after IVC filter implantation.Keywords
This publication has 34 references indexed in Scilit:
- Executive SummaryChest, 2021
- Effect of inferior vena cava filters on pulmonary embolism-related mortality and major complications: a systematic review and meta-analysis of randomized controlled trialsJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2021
- Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous ThrombosisEuropean Journal of Vascular and Endovascular Surgery, 2021
- Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic DiseaseJournal of Vascular and Interventional Radiology, 2020
- Inferior Vena Cava Filters to Prevent Pulmonary EmbolismJACC, 2017
- Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III TrialsEuropean Journal of Vascular and Endovascular Surgery, 2014
- Complications of indwelling retrievable versus permanent inferior vena cava filtersJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2014
- High Variation Between Hospitals in Vena Cava Filter Use for Venous ThromboembolismJAMA Internal Medicine, 2013
- Systematic Review of the Use of Retrievable Inferior Vena Cava FiltersJournal of Vascular and Interventional Radiology, 2011
- The Need for Anticoagulation Following Inferior Vena Cava Filter Placement: Systematic ReviewCardioVascular and Interventional Radiology, 2007